Neurofeedback in the treatment of Attention Deficit Hyperactivity Disorder

Effectiveness of neurofeedback versus methylphenidate in the treatment of children with Attention Deficit Hyperactivity Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804132000N2

Enrollment

Registered

2013-02-15

Start date

2013-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Disturbance of activity and attention

Interventions

Intervention 1: Group 1:treatment with methylphenidate started with 5mg BD and the dose will adjust in 2 weeks according to response and side effects by a child psychiatrist. Intervention 2: Group 3:t

Treatment - Drugs

Treatment - Devices

Group 1:treatment with methylphenidate started with 5mg BD and the dose will adjust in 2 weeks according to response and side effects by a child psychiatrist

Group 3:treatment with the combination of methylphenidate and neurofeedback. Both of these interventions is implemented in the same instruction as in group 1 and 2

Group 2: treatment with neurofeedback 2 times a week by an expert in a special clinic.In this method , we are going to increase beta waves in the brain and as a result increasing attention

Eligibility

Sex/Gender

All

Age

7 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-Diagnosis of ADHD based on DSM-IV-TR criteria by child and adolescent psychiatrists; 2- age of 7- 18 years; 3- IQ above 85 based on WISC-III-R; 4- parent consent for the participation in the study. Exclusion criteria: 1- neurological disorders; 2- major learning problems; 3- request of parent to exit from the study; 4- use of antipsychotic drugs in the month before the initiation of the study; 5- history of neurofeedback intervention at least for 10 sessions.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ADHD symptoms. Timepoint: 1 week before the initiation and each monththrough the study and 1 week after the end of the intervention. Method of measurement: conners ADHD rating scale.	—

Secondary

Measure	Time frame
Attention. Timepoint: 1 week before , and 1 week after the end of the trial. Method of measurement: Test of Variables of Attention.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Javad Alaghband Rad

Tehran University of Medical Sciences

alaghbandrad@gmail.com+98 21 5541 9151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026